SynthesisInflammopharmacology2025
Safety profile of glucokinase activator AZD1656: systematic review and meta-analysis of 23 randomised trials in diabetic and healthy volunteers with relevance to immunomodulatory therapy.
Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucokinase enzyme plays a pivotal role in various physiological processes such as glucose metabolism, inflammation, and immunity. AZD1656 is a glucokinase activator (GKA) that shows proven efficacy in reducing blood glucose. It also possesses a marked interest in autoimmune diseases due to its immunomodulatory effect. Six databases were searched: PubMed, Scopus, the Cochrane Library, World of Science, ClinicalTrials.gov, and AstrazenecaClinicalTrials.com. This meta-analysis was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Twenty-three randomized controlled trials were included in this systematic review, and 19 studies were included in the meta-analysis. There was no significant difference between AZD1656 and placebo. Regarding total non-serious adverse events (a/e), the cumulative relative risk (RR) was 1.09 (95% CI 0.96-1.24, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.